These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23284040)

  • 21. Fluorescence immunophenotyping and interphase cytogenetics (FICTION) detects BCL6 abnormalities, including gene amplification, in most cases of nodular lymphocyte-predominant Hodgkin lymphoma.
    Bakhirev AG; Vasef MA; Zhang QY; Reichard KK; Czuchlewski DR
    Arch Pathol Lab Med; 2014 Apr; 138(4):538-42. PubMed ID: 24678684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology.
    Hartmann S; Eray M; Döring C; Lehtinen T; Brunnberg U; Kujala P; Vornanen M; Hansmann ML
    BMC Cancer; 2014 May; 14():332. PubMed ID: 24885870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway.
    Frich L; Glattre E; Akslen LA
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):113-7. PubMed ID: 11219767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma.
    Akhtar S; Rauf MS; Al-Kofide A; Elshenawy MA; Mushtaq AH; Maghfoor I
    Hered Cancer Clin Pract; 2021 Feb; 19(1):17. PubMed ID: 33563316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.
    Sidda A; Naleid NK; Manu G; Graffeo V; Jamil MO
    J Investig Med High Impact Case Rep; 2022; 10():23247096221111767. PubMed ID: 35861500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
    Biasoli I; Stamatoullas A; Meignin V; Delmer A; Reman O; Morschhauser F; Coiffier B; Bosly A; Diviné M; Brice P
    Cancer; 2010 Feb; 116(3):631-9. PubMed ID: 20029973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.
    Ali S; Olszewski AJ
    Leuk Lymphoma; 2014 Jul; 55(7):1570-7. PubMed ID: 24067135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma.
    Bhargava P; Pantanowitz L; Pinkus GS; Pinkus JL; Paessler ME; Roullet M; Gautam S; Bagg A; Kadin ME
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):16-23. PubMed ID: 19550297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site.
    Cotta CV; Coleman JF; Li S; Hsi ED
    Histopathology; 2011 Dec; 59(6):1194-203. PubMed ID: 22175899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
    Olszewski AJ; Shrestha R; Cook NM
    Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study.
    Maule M; Scélo G; Pastore G; Brennan P; Hemminki K; Tracey E; Sankila R; Weiderpass E; Olsen JH; McBride ML; Brewster DH; Pompe-Kirn V; Kliewer EV; Chia KS; Tonita JM; Martos C; Jonasson JG; Merletti F; Boffetta P
    J Natl Cancer Inst; 2007 May; 99(10):790-800. PubMed ID: 17505074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nodular lymphocyte predominant Hodgkin's lymphoma.
    Siddiqui N; Al-Diab AI
    Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
    Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
    Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
    Gloghini A; Bosco A; Ponzoni M; Spina M; Carbone A
    Expert Rev Hematol; 2015 Apr; 8(2):217-23. PubMed ID: 25487651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma.
    Rahemtullah A; Reichard KK; Preffer FI; Harris NL; Hasserjian RP
    Am J Clin Pathol; 2006 Nov; 126(5):805-14. PubMed ID: 17050078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
    Br J Haematol; 2012 May; 157(3):321-30. PubMed ID: 22360654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
    Eichenauer DA; Hartmann S
    Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.
    Nam-Cha SH; Roncador G; Sanchez-Verde L; Montes-Moreno S; Acevedo A; Domínguez-Franjo P; Piris MA
    Am J Surg Pathol; 2008 Aug; 32(8):1252-7. PubMed ID: 18594468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.
    Tersmette AC; Petersen GM; Offerhaus GJ; Falatko FC; Brune KA; Goggins M; Rozenblum E; Wilentz RE; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Clin Cancer Res; 2001 Mar; 7(3):738-44. PubMed ID: 11297271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.